Nuvation Bio Inc [NUVB] stock prices are up 1.62% to $3.77 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NUVB shares have gain 17.08% over the last week, with a monthly amount drifted -3.33%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nuvation Bio Inc [NYSE: NUVB] stock has seen the most recent analyst activity on September 30, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $10. Previously, Citizens JMP started tracking the stock with Mkt Outperform rating on April 23, 2025, and set its price target to $6. On March 27, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $10 on the stock. BTIG Research upgraded its rating to a Buy but stick to its price target of $5 on March 26, 2024. Jefferies downgraded its rating to a Hold and reduced its price target to $2 on January 06, 2023. BTIG Research downgraded its rating to Neutral for this stock on August 02, 2022. In a note dated August 02, 2022, BMO Capital Markets downgraded an Market Perform rating on this stock and revised its target price from $8 to $2.50.
The stock price of Nuvation Bio Inc [NUVB] has been fluctuating between $1.54 and $4.09 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Nuvation Bio Inc [NYSE: NUVB] shares were valued at $3.77 at the most recent close of the market. An investor can expect a potential return of 59.15% based on the average NUVB price forecast.
Analyzing the NUVB fundamentals
The Nuvation Bio Inc [NYSE:NUVB] reported sales of 14.36M for trailing twelve months, representing a surge of 236.79%. Gross Profit Margin for this corporation currently stands at 0.28% with Operating Profit Margin at -15.65%, Pretax Profit Margin comes in at -14.13%, and Net Profit Margin reading is -14.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.46 and Total Capital is -0.39. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.55.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.65 points at the first support level, and at 3.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.88, and for the 2nd resistance point, it is at 3.99.
Ratios To Look Out For
It’s worth pointing out that Nuvation Bio Inc [NYSE:NUVB]’s Current Ratio is 9.39. As well, the Quick Ratio is 9.38, while the Cash Ratio is 3.74. Considering the valuation of this stock, the price to sales ratio is 90.12, the price to book ratio is 3.42.
Transactions by insiders
Recent insider trading involved Markel Stacy, CHIEF PEOPLE OFFICER, that happened on Jun 18 ’25 when 10000.0 shares were purchased. Chief Financial Officer, Sauvage Philippe completed a deal on Jun 17 ’25 to buy 4000.0 shares. Meanwhile, Chief Financial Officer Sauvage Philippe bought 3300.0 shares on Jun 16 ’25.
